已收盤 05-29 16:00:00 美东时间
0.000
0.00%
PennantPark Floating Rate Capital Ltd. has priced an underwritten public offering of $100 million aggregate principal amount of its 7.375% notes due 2031. The notes will mature on June 15, 2031, and may be redeemed at the company's option starting June 15, 2028. The offering is expected to close on June 1, 2026, with the notes listed on the New York Stock Exchange under the symbol "PFLA." The company has granted underwriters a 30-day option to pu...
05-27 21:45
今日重点评级关注:TD Cowen:维持Strategy"买入"评级,目标价从395美元升至400美元;摩根士丹利:维持Cipher Digital"超配"评级,目标价从40.5美元升至42.5美元
05-20 11:55
Truist Securities analyst Arren Cyganovich maintains Pennant Park Investment (NYSE:PNNT) with a Buy and lowers the price target from $6 to $5.
05-20 02:27
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
05-13 11:46
Oppenheimer analyst Mitchel Penn maintains Pennant Park Investment (NYSE:PNNT) with a Perform and lowers the price target from $6 to $5.
05-13 01:40
Pennantpark Investment (($PNNT)) has held its Q2 earnings call. Read on for the...
05-09 09:59
PennantPark Investment (PNNT) declares $0.08/share monthly dividend, in line with previous. It comprised of a $0.04 per share base dividend and $0.04 per share supplemental dividend. Payable June 1; f...
05-05 14:31
PennantPark Investment Corporation declares May 2026 monthly distribution of $0.08 per share, including $0.04 base dividend and $0.04 supplemental dividend, payable on June 1 to shareholders of record as of May 15. The distribution is expected to be paid from taxable net investment income. The company, managed by PennantPark Investment Advisers, LLC, primarily invests in U.S. middle-market private companies through secured debt and equity investm...
05-04 20:05
今日重点评级关注:HC Wainwright & Co.:维持FibroBiologics"买入"评级,目标价从4美元升至8美元;摩根士丹利:维持Ultragenyx药业"超配"评级,目标价从50美元升至67美元
04-17 11:27
Keefe, Bruyette & Woods analyst Paul Johnson maintains Pennant Park Investment (NYSE:PNNT) with a Underperform and lowers the price target from $5 to $4.5.
04-16 20:14